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Anemia in patients with severe 
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prognostic impact of anemia complicating severe aortic stenosis (As) remains unclear. We assessed the 
impact of anemia on cardiovascular and bleeding outcomes in 3403 patients enrolled in the CURRENT 
AS registry. 835 patients (25%) had mild (hemoglobin 11.0–12.9 g/dl for men/11.0–11.9 g/dl for women) 
and 1282 patients (38%) had moderate/severe anemia (Hb ≤ 10.9 g/dl) at diagnosis of severe AS. Mild 
and moderate/severe anemia were associated with significantly increased risks relative to no anemia 
(hemoglobin ≥13.0 g/dl for men/≥12.0 g/dl for women) for the primary outcome measure (aortic valve-
related death or heart failure hospitalization) in the entire population [hazard ratio (HR): 1.30; 95% 
confidence interval (CI): 1.07–1.57 and HR: 1.56; 95%CI: 1.31–1.87, respectively] and in the conservative 
management stratum (HR: 1.73; 95%CI: 1.40–2.13 and HR: 2.05; 95%CI: 1.69–2.47, respectively). 
Even in the initial aortic valve replacement stratum, moderate/severe anemia was associated with 
significantly increased risk for the primary outcome measure (HR: 2.12; 95%CI: 1.44–3.11). Moreover, 
moderate/severe anemia was associated with significantly increased risk for major bleeding while under 
conservative management (HR: 1.93; 95%CI: 1.21–3.06). These results warrant further study to explore 
whether better management of anemia would lead to improvement of clinical outcomes.
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Aortic stenosis (AS) is the most common valvular disease with poor prognosis and complex pathophysiology1,2. 
The majority of patients with AS are elderly with multiple co-morbidities causing poor functional status and 
prognosis3. Aortic valve replacement (AVR), either surgical or via a transcatheter approach, is the only therapeu-
tic option in patients with severe AS, while there is no proven medical therapy for improving the prognosis of 
severe AS4. The identification of modifiable comorbidities might lead to improvement in outcomes for patients 
with severe AS.
Anemia is common in the elderly population and is potentially treatable5. Patients with severe AS are particu-
larly susceptible to anemia, because they frequently are on antiplatelet and/or anticoagulant treatment and often 
suffer from acquired coagulopathy (von Willebrand syndrome type 2A), leading to an increased risk of bleed-
ing6,7. Because tissue oxygen supply is limited due to decreased cardiac output, the concurrent presence of even a 
mild degree of anemia may harmfully affect the disease course of severe AS. Importantly, pre-existing anemia at 
the diagnosis of severe AS might be associated with a higher risk of future bleeding events, because anemia could 
be the result from a longstanding bleeding tendency.
Several recent studies have focused on the relationship between anemia and severe AS8–11. However, most of 
those studies included only patients who underwent transcatheter aortic valve implantation (TAVI), and anemia 
was diagnosed during the periprocedural period. Given a considerable number of patients with severe AS patients 
who are under medical management or a watchful waiting strategy in daily clinical practice12, it would be perti-
nent to evaluate the prognostic impact of anemia present at the time of severe AS diagnosis.
Therefore, we comprehensively evaluated the characteristics of severe AS patients with anemia enrolled con-
secutively in a large Japanese multicenter registry and assessed the impact of anemia on cardiovascular as well as 
bleeding outcomes.
Methods
study population. The study design and primary results of the CURRENT AS (Contemporary Outcomes 
After Surgery and Medical Treatment in Patients with Severe Aortic Stenosis) registry have been previously 
reported13. Briefly, the CURRENT AS registry is a retrospective, multicenter registry that enrolled 3815 con-
secutive patients who met the definition of severe AS (i.e. peak aortic jet velocity [Vmax] > 4.0 m/s, mean aortic 
pressure gradient [PG] > 40 mmHg, or aortic valve area [AVA] < 1.0 cm2) for the first time between January 2003 
and December 2011 at 27 centers in Japan. The institutional review board or ethics committee at all 27 partic-
ipating centers approved the study protocol. Written informed consent was waived by all review boards/ethics 
committees, because we retrospectively gathered the data obtained in the routine clinical practice, and no patient 
refused to participate in the study when contacted for follow-up. The study was performed in accordance with the 
relevant guidelines and regulations.
The current study population consisted of 3403 patients with severe AS after excluding 412 patients whose 
baseline hemoglobin (Hb) values were not available. The study patients were categorized into 3 groups based on 
the baseline Hb values according to the standard World Health Organization classification of anemia: no anemia 
(Hb ≥ 13.0 g/dl for men, and ≥12.0 g/dl for women), mild anemia (Hb 11.0–12.9 g/dl for men, and 11.0–11.9 g/dl 
for women), and moderate/severe anemia (Hb < 10.9 g/dl)14. The median time between the index echocardiogra-
phy and baseline blood test was 1 day (interquartile range [IQR], 0–10 days).
Follow-up was commenced on the day of the index echocardiography. Follow-up information was collected 
primarily through review of hospital charts, and additional information was collected from patients, relatives and/
or referring physicians via a mailed questionnaire regarding survival, symptoms and subsequent hospitalizations.
Definitions of the Clinical Outcome Measures. The primary outcome measure in the present analysis 
was the AS-related clinical outcome, namely a composite of aortic valve-related death and heart failure (HF) 
hospitalization. The secondary outcome measures included the individual components of the primary outcome 
measure as well as all-cause death, cardiovascular death, sudden death, and non-cardiovascular death. Aortic 
valve-related death included aortic valve procedure death, sudden death, and death due to HF possibly related 
to AS. Causes of death were defined according to the Valve Academic Research Consortium (VARC) criteria15,16. 
HF hospitalization was defined as hospitalization due to deteriorating HF that required intravenous drug therapy. 
The severity of bleeding events was classified by using Bleeding Academic Research Consortium (BARC) types 
in accordance with the VARC-2 criteria; major and life-threatening/disabling bleeding in the present study was 
defined as BARC type 3, and type 5 (Supplementary Data)16,17. Other definitions of clinical events have been 
described previously13. A clinical event committee adjudicated all the clinical events (Supplementary Data).
statistical Analysis. We compared the baseline characteristics among the 3 groups categorized based on the 
status of anemia, and explored the independent factors associated with anemia. We also evaluated the prognostic 
impact of anemia, including stratified analyses according to the initial treatment strategies such as initial AVR 
and conservative strategies.
Categorical variables are presented as numbers and percentages; these were compared with the chi-square 
test or Fisher’s exact test. Continuous variables are expressed as the mean and standard deviation or median and 
IQR. For comparisons across the 3 groups of anemia status, we used analysis of variance or Kruskal-Wallis test.
We explored the factors associated with the presence of mild or moderate/severe anemia by the univariate and 
multivariable logistic regression models. We simultaneously included the 17 clinically relevant variables listed in 
Supplementary Table S1 as well as anemia (both mild and moderate/severe) in the model. Continuous variables 
were dichotomized according to the median value or a clinically meaningful reference value.
The cumulative incidences of the clinical events were estimated by the Kaplan–Meier method, and differ-
ences across the 3 groups were assessed with the log-rank test. The risks of mild anemia and moderate/severe 
anemia, respectively, relative to no anemia (reference) for the primary and secondary outcome measures were 
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estimated by the Cox proportional hazard models and expressed as hazard ratios (HRs) and their 95% confidence 
intervals (CIs). We used the dummy code for mild anemia and moderate/severe anemia to estimate the HRs rel-
ative to no anemia in the models. Consistent with our previous report, the 22 clinically relevant factors listed in 
Supplementary Tables S2 and S3 were included as the risk-adjusting variables and the centers were incorporated 
as the stratification variable in the multivariable Cox proportional hazard models in the entire cohort. Except for 
age, continuous variables were dichotomized by median or clinically meaningful reference values. We also per-
formed subgroup analyses stratified by clinically relevant factors, such as the initial treatment strategy (initial AVR 
and conservative), age, symptomatic status, severity of AS, left ventricular systolic function, and renal function. In 
the subgroup analysis stratified by the initial therapeutic strategy, we constructed parsimonious models with the 
6 clinically most relevant risk-adjusting variables listed in Supplementary Tables S2 and S3, because of the small 
number of patients with outcome. Other than that, the same 22 risk-adjusting variables used in the entire cohort 
were included in the multivariable Cox proportional hazard models in the subgroup analyses. For those out-
come measures with small numbers of patients with events such as sudden death and non-cardiovascular death, 
multivariable analysis was not performed. We conducted the interaction analyses using a Cox model containing 
interactive variables (a subgroup term, anemia term and anemia-by-subgroup term) and risk-adjusting variables. 
Global P for anemia-by-subgroup term was calculated as P for interaction18. For the evaluation of bleeding events, 
we censored patients at the time of AVR/TAVI, because we did not collect data on bleeding and transfusion in 
the perioperative period. Therefore, we estimated the incidences of the bleeding events specifically while under 
medical therapy. In the adjusted analyses on the risks of each anemia group for major bleeding events, the same 
22 factors as those included in the main analyses were incorporated into multivariable Cox proportional hazard 
models as the risk adjusting variables and the centers were incorporated as the stratification variable.
As a sensitivity analysis, the risks of the mild and moderate/severe anemia relative to the no anemia for the pri-
mary outcome measure and bleeding events were estimated by the Cox proportional hazard models accounting 
for the competing risk of AVR/TAVI by using the Gray method19.
All statistical analyses were performed with the statistical software program JMP 10.0.0 (SAS Institute Inc., 
Cary, NC, USA) and SAS 9.4 (SAS Institute Inc., Cary, NC, USA). All reported P values are two-tailed. P val-
ues < 0.05 were considered statistically significant.
Results
Baseline Characteristics According to the severity of Anemia. A large proportion of patients in the 
present study had anemia; there were 1286 patients (38%) without anemia, and 2117 patients (62%) with anemia, 
of whom 835 (25%) had mild anemia and 1282 (38%) had moderate/severe anemia (Fig. 1A,B). Median Hb values 
were 13.4 (IQR: 12.7–14.2) g/dl, 11.6 (11.3–11.9) g/dl, and 9.7 (8.7–10.4) g/dl in the no anemia, mild anemia, and 
moderate/severe anemia groups, respectively (P < 0.001). Baseline characteristics differed significantly across 
the 3 groups (Table 1). Overall, patients with moderate/severe anemia were older, more likely to be female, had 
lower body mass index (BMI), were less likely to have dyslipidemia and more often had a history of HF or malig-
nancy than those with no or mild anemia (Table 1). Patients in the 2 anemia groups more often had a history 
of percutaneous coronary intervention or coronary artery bypass graft and history of aortic/peripheral vascu-
lar diseases than those without anemia. Serum creatinine, brain-derived natriuretic peptide (BNP), C-reactive 
protein (CRP) and surgical risk scores were higher with increasing severity of anemia (Table 1). Regarding the 
echocardiographic parameters, compared with patients with no or mild anemia, those with moderate/severe 
anemia had lower Vmax, smaller AVA, lower left ventricular ejection fraction, thinner wall thickness and greater 
tricuspid regurgitation PG (Table 1). Proportion of patients with low gradient severe AS (Vmax ≤ 4 m/s and mean 
aortic PG ≤ 40 mmHg, but AVA < 1.0 cm2) was higher in the patients with moderate/severe anemia as compared 
with those with no or mild anemia. An initial AVR strategy was selected in 1178 patients (35% of the cohort), 
of whom 1156 (98.1%) actually underwent surgical AVR (n = 1145) or TAVI (n = 11) at a median interval of 36 
(IQR: 16–60) days from the index echocardiography (Table 1). Among the remaining 2225 patients for whom the 
conservative strategy was initially selected, 451 (20.3%) eventually underwent surgical AVR (n = 429) or TAVI 
(n = 23) at a median interval of 756 (IQR: 270–1268) days from the index echocardiography (Table 1). Initial 
AVR strategy was selected less often, and AVR or TAVI was performed less often as the anemia severity increased 
(Table 1). Further detailed data on baseline characteristics were provided in Supplemental Table S2.
Factors Associated with Anemia. Variables independently associated with anemia included older age, 
female gender, lower BMI, coronary artery disease and aortic/peripheral disease, renal failure, prior HF, malig-
nancy, liver cirrhosis, and higher tricuspid regurgitation PG (≥40 mmHg) (Supplementary Table S1).
primary outcome Measure According to the severity of Anemia: entire Cohort. The cumulative 
5-year incidence of the primary outcome measure (a composite of aortic valve-related death and HF hospitali-
zation) increased with increasing severity of anemia (22%, 34%, and 56% in the no, mild, and moderate/severe 
anemia groups, respectively; P < 0.001) (Fig. 2A). Even after adjusting for potential confounders, the excess risk 
of the mild and moderate/severe anemia groups relative to the no anemia group for the primary outcome measure 
remained significant (HR: 1.30; 95% CI: 1.07–1.57; P = 0.008, and HR: 1.56; 95% CI: 1.31–1.87; P < 0.001, respec-
tively) (Table 2). When we censored the patients at the time of AVR/TAVI to evaluate the impact of anemia while 
under conservative management, the excess risks of the 2 anemia groups relative to the no anemia group for the 
primary outcome measure remained significant (adjusted HR: 1.46; 95% CI: 1.17–1.82; P < 0.001, and adjusted 
HR: 1.69; 95% CI: 1.38–2.07; P < 0.001, respectively).
In the subgroup analyses, there were no significant interactions between the subgroup factors and the effect of 
anemia on the primary outcome measure except for the subgroups stratified by renal function (Supplementary Fig. S2).
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Primary Outcomes Measure According to the Severity of Anemia Stratified by Initial Therapeutic 
strategy. In the conservative stratum, the cumulative 5-year incidence of AVR or TAVI decreased with 
increasing severity of anemia (43%, 37%, and 25%, respectively, P < 0.001), whereas in the initial AVR stra-
tum, the vast majority of patients underwent AVR or TAVI regardless of the severity of anemia (Supplementary 
Fig. S3A,B). Regardless of the initial treatment strategies (initial AVR and conservative), the effects of anemia 
severity for the primary outcome measure were generally in the same direction as those in the entire cohort 
with no positive interaction between anemia severity and the initial therapeutic strategies (interaction P = 0.2) 
(Table 2), although the outcomes of each anemia group were remarkably better in the AVR than in the conserv-
ative stratum (Fig. 2B,C).
secondary outcome Measures According to the severity of Anemia. The effects of the severity 
of anemia for the secondary outcome measures such as aortic valve-related death, HF hospitalization, all-cause 
death and cardiovascular death were generally in the same direction as for the primary outcome measure in the 
entire cohort, and in the conservative stratum (Table 2, and Supplementary Fig. S1). In the initial AVR stratum, 
moderate/severe anemia as compared with no anemia was associated with significantly higher risk for all the sec-
ondary outcome measures, whereas mild anemia as compared with no anemia was associated with significantly 
higher risk only for all-cause death, cardiovascular death and non-cardiovascular death (Table 2). There were no 
significant interactions between the initial therapeutic strategies and the effect of anemia on the secondary out-
come measures (interaction P = 0.08, 0.7, 0.2 and 0.06 for aortic valve-related death, HF hospitalization, all-cause 
death and cardiovascular death, respectively).
Figure 1. (A) Histograms of hemoglobin levels. (B) Study flowchart AS = aortic stenosis, AVR = aortic valve 
replacement.
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Bleeding events Under Conservative Management. In the entire cohort, 152 (4.5%) patients had 
major or life-threatening bleeding events while under conservative management. The cumulative 5-year inci-
dence of bleeding events was incrementally higher with the increasing severity of anemia (7%, 12%, and 18%, 
respectively, P < 0.001) (Fig. 3A). After adjusting for the potential confounders, the excess risk of the moderate/
severe anemia group relative to the no anemia group remained highly significant (HR: 1.93; 95%CI: 1.21–3.06; 
P = 0.005), whereas no significant increased risk was observed for the mild anemia group relative to the no ane-
mia group (adjusted HR: 1.15, 95%CI: 0.69–1.91, P = 0.6). Gastrointestinal (55%) and intracranial bleeding (22%) 
were the two main bleeding sites (Fig. 3B). One-third of the bleeding events was major bleeding (BARC type 3a), 
whereas two-thirds of the bleeding events were life-threatening or disabling bleeding (BARC types 3b, 3c and 5) 
(Fig. 3C).
Variables
No anemia Hb ≥ 13.0 g/dl  
for men, and ≥12.0 g/dl 
for women
Mild anemia Hb 
11.0–12.9 g/dl for men, and 
11.0–11.9 g/dl for women
Moderate/Severe 
anemia Hb ≤ 10.9 g/dl
P valueN = 1286 N = 835 N = 1282
Clinical characteristics
Age, y 74.5 ± 9.9 78.0 ± 8.7 81.4 ± 8.7 <0.001
Men 524 (41) 399 (48) 371 (29) <0.001
BMI, kg/m2 22.7 ± 3.7 22.0 ± 3.7 20.6 ± 3.6 <0.001
Hypertension 879 (68) 598 (72) 923 (72) 0.09
Current smoking 87 (7) 51 (6) 37 (3) <0.001
Dyslipidemia 514 (40) 308 (37) 372 (29) <0.001
Diabetes mellitus 296 (23) 209 (25) 323 (25) 0.4
Coronary artery disease 341 (27) 304 (36) 398 (31) <0.001
Prior PCI 126 (10) 132 (16) 189 (15) <0.001
Prior CABG 38 (3) 58 (7) 72 (6) <0.001
Prior myocardial infarction 73 (6) 78 (9) 132 (10) <0.001
Prior HF 158 (12) 119 (14) 314 (24) <0.001
Aortic/peripheral vascular disease 156 (12) 152 (18) 227 (18) <0.001
Serum creatinine, mg/dl 0.8 (0.6–1.0) 0.9 (0.7–1.2) 1.1 (0.8–2.3) <0.001
Hemoglobin, g/dl 13.4 (12.7–14.2) 11.6 (11.3–11.9) 9.7 (8.7–10.4) <0.001
BNP, pg/ml 143 (57–432) 216 (97–615) 554 (202–1357) <0.001
CRP, mg/dl 0.13 (0.06–0.36) 0.2 (0.08–0.64) 0.43 (0.1–2.2) <0.001
Malignancy 145 (11) 114 (14) 216 (17) <0.001
Chronic lung disease 159 (12) 88 (11) 119 (9) 0.04
Logistic EuroSCORE, % 7.0 (4.2–12.0) 9.4 (6.2–16.0) 14.2 (9.0–23.0) <0.001
EuroSCORE II,% 1.9 (1.2–3.5) 2.8 (1.7–4.5) 4.1 (2.7–6.8) <0.001
STS score (PROM), % 2.5 (1.6–4.0) 3.8 (2.4–5.9) 6.1 (3.7–1.0) <0.001
Echocardiographic variables
Vmax, m/s 4.2 ± 0.9 4.2 ± 0.9 4.1 ± 0.9 0.01
Mean aortic PG, mmHg 42 ± 20 42 ± 21 41 ± 20 0.09
AVA (equation of continuity), cm2 0.73 ± 0.18 0.72 ± 0.18 0.69 ± 0.19 <0.001
Low gradient AS (Vmax ≤ 4 m/s and mean 537 (42) 356 (43) 597 (47) 0.04
aortic PG ≤ 40 mmHg, but AVA < 1.0 cm2)
LVEF, % 64 ± 13 63 ± 13 61 ± 14 <0.001
IVST in diastole, mm 11.5 ± 2.4 11.5 ± 2.3 11.2 ± 2.2 0.002
PWT in diastole, mm 11.1 ± 2.0 11.1 ± 2.2 10.9 ± 2.0 0.04
TR pressure gradient ≥40 mm Hg 158 (12) 117 (14) 292 (23) <0.001
Therapeutic strategy
Initial AVR 549 (43) 316 (38) 313 (24) <0.001
Conservative 737 (57) 519 (62) 969 (76) <0.001
Table 1. Baseline Characteristics According to the Status of Anemia. Values are mean ± SD, median 
(interquartile range), or number (%). The values of CRP and BNP were obtained in 2914 (76%) and 1801 (47%) 
patients, respectively. Further detailed data on baseline characteristics were provided in Supplemental Table S2. 
AS = aortic stenosis; AVA = aortic valve area; AVR = aortic valve replacement; BMI = body mass index; 
BNP = brain-derived natriuretic peptide; CABG = coronary artery bypass grafting; CRP = C-reactive protein; 
Hb = hemoglobin; HF = heart failure; IVST = interventricular septum thickness, LVEF = left ventricular 
ejection fraction; PCI = percutaneous coronary intervention; PG = pressure gradient; PROM = predicted risk 
of mortality; PWT = posterior wall thickness; STS = Society of Thoracic Surgeons; TR = tricuspid regurgitation; 
Vmax = peak aortic jet velocity.
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Sensitivity analysis for the excess risk of anemia accounting for the competing risk of AVR/TAVI. 
Sensitivity analysis confirmed that even when the competing risk of AVR/TAVI was accounted for, the excess 
risks relative to the no anemia group for the primary outcome measure remained significant in both the mild 
(unadjusted HR: 1.75; 95% CI: 1.43–2.15; P < 0.001, adjusted HR: 1.43; 95% CI: 1.15–1.77; P = 0.001) and the 
moderate/severe anemia group (unadjusted HR: 3.45; 95% CI: 2.90–4.10; P < 0.001, adjusted HR: 1.60; 95% CI: 
1.30–1.96; P < 0.001). Likewise, the adjusted excess risk of the moderate/severe anemia group relative to the no 
anemia group for the major or life-threatening bleeding events remained highly significant (unadjusted HR: 3.33; 
Figure 2. Kaplan–Meier curves for the primary outcome measure according to the severity of anemia. (A) 
Entire cohort. (B) Conservative stratum. (C) Initial AVR stratum. The primary outcome measure was defined 
as a composite of aortic valve-related death of heart failure hospitalization. Severity of anemia was classified as 
no anemia (Hb ≥ 13.0 g/dl for men, and≥12.0 g/dl for women), mild anemia (Hb 11.0–12.9 g/dl for men, and 
11.0–11.9 g/dl for women), and moderate/severe anemia (Hb ≤ 10.9 g/dl). AVR = aortic valve replacement, and 
Hb = hemoglobin.
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95% CI: 2.24–4.94; P < 0.001, adjusted HR: 1.92; 95% CI: 1.24–2.99; P = 0.004) even when the competing risk of 
AVR/TAVI was accounted for, whereas no significant excess risk relative to the no anemia group was observed in 
the mild anemia group (unadjusted HR: 1.57; 95%CI: 0.97–2.53, P = 0.07, adjusted HR: 1.92; 95% CI: 1.24–2.99; 
P = 0.004).
No anemia Mild anemia versus No anemia Moderate/Severe anemia versus No anemia
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Aortic valve-related death 80 (16) 105 (31) 2.04(1.55–2.69) <0.001
1.90





HF hospitalization 129 (26) 134 (39) 1.71(1.36–2.16) <0.001
1.63





All-cause death 207 (36) 224 (54) 1.79(1.50–2.15) <0.001
1.52





Cardiovascular death 125 (23) 155 (41) 1.94(1.55–2.43) <0.001
1.76





Sudden death 25 (4) 36 (10) 2.01(1.26–3.21) 0.003 N/A 73 (15)
2.7
(1.8–4.19) <0.001 N/A
Non-cardiovascular death 82 (17) 69 (21) 1.54(1.13–2.10) 0.006 N/A 199 (33)
2.92
(2.27–3.78) <0.001 N/A
Initial AVR Stratum (N = 1178)
Primary outcome measure
Aortic valve-related death 










Aortic valve-related death 21 (4) 14 (5) 1.21(0.6–2.4) 0.6
1.16





HF hospitalization 29 (7) 24 (11) 1.5(0.91–2.45) 0.1
1.30





All-cause death 56 (13) 58 (25) 1.89(1.34–2.67) <0.001
1.88





Cardiovascular death 38 (9) 34 (15) 1.66(1.06–2.58) 0.03
1.70





Sudden death 9 (2) 4 (2) 0.86(0.27–2.38) 0.8 N/A 11 (10)
2.37
(1.01–5.57) 0.03 N/A
Non-cardiovascular death 18 (5) 24 (12) 2.34(1.34–4.12) 0.005 N/A 30 (16)
3.36
(1.97–5.83) <0.001 N/A
Table 2. Crude and Adjusted Effects of Anemia for Clinical Outcomes. AVR = aortic valve replacement; 
CI = confidence interval; HF = heart failure; HR = hazard ratio.
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Discussion
In a large cohort of patients with severe AS, we found that more than 60% of patients had anemia at the time of 
severe AS diagnosis. Moderate/severe anemia was associated with extremely worse prognosis with increased risk 
for AS-related adverse events regardless of the therapeutic strategy. Even a mild degree of anemia was associated 
Figure 3. Relationship between anemia and bleeding events under conservative management. (A) Kaplan–
Meier curves for major or life-threatening bleeding events under conservative management in the entire cohort. 
(B,C) Sites (B) and severity (C) of bleeding under conservative management in the entire cohort of bleeding. 
Cumulative incidence of major or life-threatening/disabling bleeding events under conservative management 
was estimated by the Kaplan-Meier method with censoring at AVR/TAVI. AVR = aortic valve replacement, 
BARC = Bleeding Academic Research Consortium, and TAVI = transcatheter aortic valve implantation.
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with significantly worse prognosis in the entire population and in the patients who were medically managed. 
Furthermore, moderate/severe anemia was associated with increased risk of major or life-threatening bleeding 
while under medical therapy.
Previous reports are limited for the prognostic impact of Hb levels at severe AS diagnosis. In one study 
exploring the relationship between baseline anemia and prognosis in 856 AS patients, the prevalence of anemia 
increased with increasing severity of AS, and anemia was independently associated with increased all-cause mor-
tality while under medical therapy, but not after AVR surgery9. Of note, the patients included in that study were 
much younger (mean age, 71 years) than those in our study and had less severe AS, with more than 50% of their 
patients having moderate AS. This may be related to a much lower prevalence of anemia in their cohort (32%) 
as compared with ours (63%). In other cohorts including the patients who underwent TAVI, the prevalence of 
preoperative anemia was 45–64%8,10,20,21. We found several predisposing factors to anemia such as older age, 
low BMI, a history of HF, coronary artery disease and aortic/peripheral disease, renal failure and malignancy. 
The results may reflect the growing prevalence of severe AS in the elderly population with multiple comorbidi-
ties3, and all these factors may synergistically contribute to the extremely poor prognosis in severe AS patients 
associated with anemia. Particularly, end-stage renal function deleteriously affects the prognosis of severe AS, as 
reported in our previous study22. Nevertheless, even after careful adjustment for a broad array of baseline char-
acteristics including renal function, we still found anemia to be a strong indicator of poor prognosis. AVR/TAVI 
strategy was selected less often in patients with higher-grade anemia, which might have increased the rate of clin-
ical events in the entire cohort. However, even in the initial AVR stratum in which more than 98% of the patients 
underwent AVR, the cumulative 5-year incidence of the primary outcome measure still was incrementally higher 
with increasing severity of anemia. Furthermore, even a mild degree of anemia was associated with significantly 
worse outcomes; its deleterious effect was prominent in those patients with advanced age, without symptoms, 
without ‘very severe’ AS (Vmax < 5 m/s) and with preserved left ventricular systolic function (ejection fraction 
≥50%). Notably, these factors might predispose to the selection of conservative strategy rather than initial AVR 
strategy13,23,24. Importantly, in contrast to the previous reports from TAVI cohorts, our study enrolled consecutive 
patients with severe AS, and therefore, included substantial proportion of patients who were managed conserv-
atively8,10,11. Negative prognostic impact of anemia was more prominent in patients with a conservative strategy 
than in those with an initial AVR strategy. Given these results, together with lack of effective medical management 
for severe AS4,23,25, anemia might be an important target of medical management in patients with severe AS. For 
example, iron therapy, which has been proven for improving the functional status of chronic HF patients, might 
be a viable therapeutic option for patients with severe AS, which should be evaluated in prospective studies26,27.
We found that the patients with baseline anemia had an elevated risk of major or life-threatening bleed-
ing events as compared with those without anemia. Similarly, Philippe et al. reported that the presence of low 
Hb levels at baseline was significantly associated with major bleeding complications within 30 days of surgical 
AVR28. The presence of anemia at severe AS diagnosis could be the result from longstanding bleeding tendency, 
possibly due to the continuous prescription of antithrombotic drugs, or von Willebrand syndrome type 2A7,29. 
Importantly, the presence of anemia at the diagnosis of severe AS often might be regarded as ‘not severe’, espe-
cially in elderly patients. However, given the highly significant association between the presence of anemia and 
the extremely poor prognosis demonstrated in our study, we might have need to pay more attention to anemia in 
patients with severe AS.
Limitations. This study had several limitations. First, anemia was evaluated only at baseline. Therefore, the 
subsequent change in Hb and its relationship with the prognosis remained unclear. Second, the relationship 
between baseline anemia and the incidence of AVR/TAVI-related bleeding events remains unclear, because our 
study focused more on the bleeding events under conservative management rather than on procedure-related 
events. Third, to keep consistency with our previous reports, the same clinically relevant factors as in our pre-
vious reports were included as the risk-adjusting variables in the Cox proportional hazard models. However, 
this strategy might result in overfitting models particularly in the analyses for some secondary outcomes and 
bleeding events. Fourth, patients with anemia were more likely to be frail, have a history of HF, malignancy and 
coronary artery or aortic/peripheral disease than those without anemia. In addition, they were more likely to have 
higher BNP, CRP and surgical risk scores. Despite an extensive statistical adjustment for potential confounders 
obtained in our registry, we cannot deny the residual unmeasured confounders such as frailty30. Finally, it should 
be acknowledged that the CURRENT AS registry included mostly Asian patients and, hence, limits the general-
izability of the study to mostly Asian patients with AS.
(Contemporary Outcomes After Surgery and Medical Treatment in Patients With Severe Aortic Stenosis 
Registry; UMIN000012140). https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014041.
Conclusions
Anemia is a common comorbidity in patients with severe AS and is associated with worse cardiovascular as 
well as bleeding outcomes. Further study should be warranted to explore whether better management of anemia 
would lead to improvement of clinical outcomes.
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